Figure 2.
Treatment-outcome phenotypes. Subjects who completed at least 6 wk of treatment with citalopram were assigned a remission and response phenotype that was based on the QIDS-C16 score at the last treatment visit. Those who met score criteria for remission or response after 3–6 wk of treatment were grouped with probable remitters or probable responders, respectively.